Clinical Trial Update: Study To Evaluate The Immunogenicity And Safety Of r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the immunogenicity and safety of recombinant human interferon beta-1a (Rebif) using Clone 484-39 in adults with relapsing-remitting mul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Rebif (interferon beta-1a)

Snippet

Sponsor: Merck KGaA, Darmstadt, Germany | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2010-08-27